Findings persist even after accounting for subsequent CVD risk factors
WEDNESDAY, Oct. 26, 2022 (HealthDay News) — Irregular and long menstrual cycles are associated with increased rates of cardiovascular disease (CVD), according to a study published online Oct. 25 in JAMA Network Open.
Yi-Xin Wang, M.D., Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues explored associations between menstrual cycle characteristics across the reproductive life span and the risk for CVD. The analysis included 80,630 participants in the Nurses’ Health Study II with 24 years of follow-up.
The researchers found that compared with women reporting very regular cycles at the same ages, women who had irregular cycles or no periods at ages 14 to 17, 18 to 22, or 29 to 46 years had a higher risk for CVD (hazard ratios [95 percent confidence intervals], 1.15 [0.99 to 1.34], 1.36 [1.06 to 1.75], and 1.40 [1.14 to 1.71], respectively). Women reporting a cycle length ≥40 days or a cycle too irregular to estimate from ages 18 to 22 or 29 to 46 years also had higher CVD risk (hazard ratios [95 percent confidence intervals], 1.44 [1.13 to 1.84] and 1.30 [1.09 to 1.57], respectively) compared with women reporting a cycle length of 26 to 31 days. Subsequent development of hypercholesterolemia, chronic hypertension, and type 2 diabetes only explained 5.4 to 13.5 percent of the observed associations.
“These results suggest that menstrual cycle characteristics throughout the reproductive lifespan may be used as additional markers of CVD risk in women,” the authors write.
One author disclosed financial ties to the pharmaceutical industry.
Model May Help Identify Women at Risk for Overactive Bladder
Transdermal HRT Improves BMD in Functional Hypothalamic Amenorrhea
Testing Menstrual Blood Comparable in HPV Diagnostic Accuracy to Clinician-Collected Cervical Samples
IV Iron Dextran Cost-Effective for Managing Iron-Deficiency Anemia
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines